CN106413714A - (r)‑吡吲哚及其药学上可接受的盐的药学用途 - Google Patents
(r)‑吡吲哚及其药学上可接受的盐的药学用途 Download PDFInfo
- Publication number
- CN106413714A CN106413714A CN201480078733.5A CN201480078733A CN106413714A CN 106413714 A CN106413714 A CN 106413714A CN 201480078733 A CN201480078733 A CN 201480078733A CN 106413714 A CN106413714 A CN 106413714A
- Authority
- CN
- China
- Prior art keywords
- pain
- pirlindole
- pharmaceutically acceptable
- acceptable salt
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950002220 pirlindole Drugs 0.000 title claims abstract description 58
- 150000003839 salts Chemical class 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title description 21
- 208000002193 Pain Diseases 0.000 claims abstract description 102
- 230000036407 pain Effects 0.000 claims abstract description 97
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 208000004296 neuralgia Diseases 0.000 claims description 32
- 208000021722 neuropathic pain Diseases 0.000 claims description 29
- 229940035676 analgesics Drugs 0.000 claims description 21
- 239000000730 antalgic agent Substances 0.000 claims description 21
- 239000005557 antagonist Substances 0.000 claims description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229960005489 paracetamol Drugs 0.000 claims description 6
- -1 Fluorine ester Chemical class 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000623 carbamazepine Drugs 0.000 claims description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004031 partial agonist Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960000590 celecoxib Drugs 0.000 claims description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims description 3
- 229960004945 etoricoxib Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 claims description 3
- 229960001816 oxcarbazepine Drugs 0.000 claims description 3
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 3
- 229960000371 rofecoxib Drugs 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 2
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 claims description 2
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 claims description 2
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004420 aceclofenac Drugs 0.000 claims description 2
- 229960004892 acemetacin Drugs 0.000 claims description 2
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 229960001671 azapropazone Drugs 0.000 claims description 2
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims description 2
- 229960005430 benoxaprofen Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- OLLZVOGJEBTAQV-UHFFFAOYSA-N butan-2-one;naphthalene Chemical compound CCC(C)=O.C1=CC=CC2=CC=CC=C21 OLLZVOGJEBTAQV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002783 dexketoprofen Drugs 0.000 claims description 2
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 claims description 2
- 229960004590 diacerein Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960005293 etodolac Drugs 0.000 claims description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001493 etofenamate Drugs 0.000 claims description 2
- 229960001395 fenbufen Drugs 0.000 claims description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001419 fenoprofen Drugs 0.000 claims description 2
- 229960002679 fentiazac Drugs 0.000 claims description 2
- 229960000489 feprazone Drugs 0.000 claims description 2
- 229960004369 flufenamic acid Drugs 0.000 claims description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 229960004187 indoprofen Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 229960002202 lornoxicam Drugs 0.000 claims description 2
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims description 2
- 229960003464 mefenamic acid Drugs 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 230000008587 neuronal excitability Effects 0.000 claims description 2
- 229960000916 niflumic acid Drugs 0.000 claims description 2
- 229960000965 nimesulide Drugs 0.000 claims description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims description 2
- 229940127240 opiate Drugs 0.000 claims description 2
- 229960000273 oxametacin Drugs 0.000 claims description 2
- AJRNYCDWNITGHF-UHFFFAOYSA-N oxametacin Chemical compound CC1=C(CC(=O)NO)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AJRNYCDWNITGHF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002739 oxaprozin Drugs 0.000 claims description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004662 parecoxib Drugs 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960000851 pirprofen Drugs 0.000 claims description 2
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229960000825 proglumetacin Drugs 0.000 claims description 2
- PTXGHCGBYMQQIG-UHFFFAOYSA-N proglumetacin Chemical compound C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CCC(=O)OCCCN(CC1)CCN1CCOC(=O)CC(C1=CC(OC)=CC=C11)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 PTXGHCGBYMQQIG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012744 reinforcing agent Substances 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- 229960003676 tenidap Drugs 0.000 claims description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims description 2
- 229960002871 tenoxicam Drugs 0.000 claims description 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims description 2
- 229940015849 thiophene Drugs 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 229960002905 tolfenamic acid Drugs 0.000 claims description 2
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- IWYDHOAUDWTVEP-SSDOTTSWSA-M (R)-mandelate Chemical compound [O-]C(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-M 0.000 claims 1
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 claims 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 claims 1
- 241000349750 Baphia nitida Species 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims 1
- 229960004028 eslicarbazepine Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 229960004534 orgotein Drugs 0.000 claims 1
- 108010070915 orgotein Proteins 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- 229960003414 zomepirac Drugs 0.000 claims 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 33
- 230000002093 peripheral effect Effects 0.000 description 18
- 230000000202 analgesic effect Effects 0.000 description 17
- 210000005036 nerve Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 229940124636 opioid drug Drugs 0.000 description 13
- 230000035807 sensation Effects 0.000 description 13
- 239000000556 agonist Substances 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 208000033808 peripheral neuropathy Diseases 0.000 description 10
- 210000001835 viscera Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 201000001119 neuropathy Diseases 0.000 description 8
- 230000007823 neuropathy Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- 208000001294 Nociceptive Pain Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000005518 mononeuropathy Diseases 0.000 description 6
- 208000035824 paresthesia Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010065952 Hyperpathia Diseases 0.000 description 5
- 206010029216 Nervousness Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 206010053552 allodynia Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010064012 Central pain syndrome Diseases 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 4
- 206010036105 Polyneuropathy Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000007824 polyneuropathy Effects 0.000 description 4
- 230000001107 psychogenic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000020431 spinal cord injury Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000001379 nervous effect Effects 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 108091008700 nociceptors Proteins 0.000 description 3
- 229940121367 non-opioid analgesics Drugs 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229960002790 phenytoin sodium Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960004380 tramadol Drugs 0.000 description 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 206010009346 Clonus Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 208000001308 Fasciculation Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical class C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 108010017796 epoxidase Proteins 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000000215 hyperchromic effect Effects 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000273 spinal nerve root Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 150000008085 4,5-dihydro-1H-imidazoles Chemical class 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 241000370279 Idiosoma Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010067722 Toxic neuropathy Diseases 0.000 description 1
- 231100000126 Toxic neuropathy Toxicity 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000003943 catecholamines Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229940093334 flomax Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- YXOJQZUTQNTJHH-UHFFFAOYSA-N heptanoic acid;octadecanoic acid Chemical compound CCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O YXOJQZUTQNTJHH-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
(R)‑吡吲哚或其药学上可接受的盐以及包括其的药物组合物用于疼痛的预防和治疗处理。
Description
技术领域
本发明涉及(R)-吡吲哚对映体或其药学上可接受的盐及其组合物用于治疗和预防疼痛。
背景技术
疼痛病症的治疗在医学中是最重要的,这引起对于治疗和预防的另外疗法的世界范围的需求。
疼痛是患者寻求医疗护理的最常见的症状。虽然没有精确的定义,但它可以被定义为包括与实际或潜在损伤相关或与这种损伤有关描述的任何不愉快的感觉和情感体验(国际疼痛研究协会,IASP)。
疼痛是一种非常相关的症状,其呈现复杂的发病机制。在医学的大量的综合征和疾病中描述了疼痛。在严重的形式中,疼痛转化为多种性质的残疾、进行日常活动困难、干扰情绪、专业成绩和社会关系。
此外,疼痛的解释因个体而异,对于各个体自身,在其生命不同时间,根据变化的生理,社会文化和情感状况的变化。
关于位置分布,可以区分三种类型的疼痛:外周疼痛,中枢性疼痛和心因性疼痛。
外周疼痛是外周神经纤维中的组织疾病的结果,其在传递神经冲动时产生疼痛的感觉。外周疼痛进一步分为浅外周疼痛和深外周疼痛。第一种是急性和穿透性的,它位于起源处。深外周疼痛可分为躯体的或内脏的。躯体的深外周疼痛可以是局部的(疼痛位于疼痛刺激的起源处)或辐射的(疼痛是扩散的并且远离疼痛刺激的起源处)。最后,深的内脏外周疼痛具有难以限制的位置。
中枢性疼痛是自发性疼痛,其由诸如脊髓索、延髓,丘脑或大脑皮层等的中枢神经中枢的神经损伤引起。
心因性疼痛定义为不具有组织基质的痛苦感觉。它是专属于精神性的任何疼痛,其具有特定的解剖位置。
从病理生理学角度看,疼痛可以是伤害性或神经性的。
伤害性疼痛可以定义为由对非神经性组织的实际或威胁性的损伤引起的疼痛,并且是由伤害感受器的激活引起。伤害性疼痛可以分为躯体的或内脏的。躯体疼痛是由于躯体组织(例如骨、关节、肌肉或皮肤)中的伤害感受受体的激活引起。在内脏疼痛中,内脏伤害感受器由不同的病理机制(例如机械损伤、炎症、辐射、毒性剂)激活。内脏和躯体伤害性疼痛可以是急性或慢性的。内脏疼痛更难以表征并对常规疼痛治疗较不敏感。一些疼痛综合征(例如,癌症疼痛)包括内脏和躯体伤害性疼痛的原理。
神经性疼痛可以定义为作为影响体感系统(即外周神经、背根神经节或背根或中枢神经系统)的损伤或疾病的直接结果而产生的疼痛。
已知对神经组织产生损伤或功能障碍的几乎任何病理过程可以被认为是神经性疼痛的潜在原因:病毒、细菌、无菌性炎症、由于肿瘤或其他结构性损伤引起的压力、退行性、局部缺血、自身免疫、有毒、创伤或内分泌/代谢机制都涉及神经性疼痛的产生。
然而,最常研究的神经性疼痛病症包括糖尿病性神经性疼痛(糖尿病NP)、疱疹后神经痛(PHN)、三叉神经痛和中枢神经性疼痛(脊髓损伤(SCI)、中枢性中风后疼痛(CPSP)和多发性硬化相关疼痛)。
其它神经性疼痛病症包括与HIV感染(HIV神经病变)、创伤后或手术后神经性疼痛、慢性神经根病变、癌相关神经性疼痛、幻痛和多病原性神经性疼痛相关的神经病变。
神经病变是影响神经的功能的障碍或病理变化。如果其涉及单个神经干,其被称为单一神经病变,如果其相继涉及若干神经干,则其被称为多病灶性单一神经病变,如果涉及(弥漫性双侧)若干神经干,它被称为多发性神经病变。
外周神经病变可以是感觉的、机动的或自主的。最常见的机动临床表现是肌肉痉挛、阵挛、肌束震颤、肌肉萎缩和肌肉力量或灵巧性的丧失。
消极的感官临床表现包括痛觉减退和感觉减退。反过来,积极的感官临床表现(除了刺痛感、麻刺感或耳鸣之外)包括感觉异常、感觉迟钝、痛觉过敏(hyperpathia和hyperalgesia)和痛觉超敏。神经病变的实例包括外周多发性神经病变,其特征在于脚和指尖的烧灼感或针刺感,其由于行走、痛觉超敏、足部感觉减退和无跟腱反射而恶化;三叉神经痛,其特征在于严重的急性疼痛、在上唇和鼻子中具有持续数秒的电击样痛,其在咀嚼或刷牙时恶化,并且不伴随神经学检查的变化;腕管综合征,其特征在于在手的第一、第二和第三指和手掌表面的急性疼痛、麻刺感和降低的敏感性,其在夜间恶化,在拇指外展和屈腕试验(Phalen test)中肌肉力量减少;股外侧皮神经的单一神经病变,其特征在于对大腿侧面的烧灼和刺痛感以及皮肤过敏性的限定区域的存在;疱疹后神经痛,其特征在于在出现囊泡后在胸腔区域具有横幅状分布的灼痛(其在皮肤愈合后不会改善),增色皮肤斑和痛觉超敏。
疼痛对个人和社会福利的影响在最近几十年有所增加。
为此,神经性疼痛被广泛地认为是治疗起来最困难的疼痛综合征之一,并且结果通常不令人满意。据估计,神经性疼痛折磨高达7-8%的欧洲普通人群(EuropeanFederation of Neurological Societies guidelines on the pharmacologicaltreatment of neuropathic pain,欧洲神经病学学会联合会神经病理性疼痛的药物治疗指南,2010)。
神经性疼痛的管理是复杂的尝试,并且通常对患者和医生而言都是令人沮丧的。作用机制为不旨在改变潜在的病理生理过程或以辅助治疗剂量给药的药物经常用于治疗疼痛,更不用说用于治疗神经性疼痛。
这源于对药物作用机制的相对不完全的理解以及目前可用的镇痛药功效有限。治疗方法在医生之间差异很大,顽固的慢性疼痛综合征需要跨学科方法和更有效的药物疗法。
镇痛药物的使用遵循逐步的方法。第一步对应轻度疼痛,应用非阿片类镇痛药(抗炎药和扑热息痛)治疗;第二步是中度疼痛,指示弱阿片类药物,在第三步中,对于严重疼痛,指示使用强阿片类药物。根据疼痛的强度,应当在适当剂量下在相应的水平开始治疗。如果疼痛持续或恶化,应优化药物剂量。
镇痛药可分为两大类:非阿片类镇痛药和阿片类镇痛药。
非阿片类镇痛药包括扑热息痛和非类固醇抗炎药(NSAIDs)。扑热息痛作用机制并不是公知的,尽管假设是中枢作用。急性或慢性的大剂量给药涉及与巯基消耗相关的肝毒性的风险。
非类固醇抗炎药通过抑制环氧酶(COX)而起作用,环氧酶(COX)抑制参与炎症过程和疼痛的前列腺素(PG)的合成。它们可以非选择性的抑制COX1和COX2,如乙酰水杨酸(AAS)、布洛芬或双氯芬酸,或选择性仅抑制COX2,如塞来考昔、罗非昔布或依托考昔。非类固醇抗炎药存在几种副作用,包括胃肠道(恶心、上腹痛、溃疡、出血)、肾脏(急性肾衰竭、间质性肾炎)、血液学(血小板抗聚集、出血)或过敏反应。非选择性的非类固醇抗炎药(NSAIDs)的这些副作用最为声名狼藉。COX2抑制剂的主要副作用是通过抑制前列环素而增加心血管病的风险。非类固醇抗炎药治疗与胃肠道不良反应的风险增加相关。
所称的弱阿片类药物包括曲马多、氢可酮和右丙氧芬等。由于这些药物在高剂量下不良反应的发生率增加,而具有最大剂量学。曲马多是可待因的合成衍生物,其通过结合阿片类药物μ受体并抑制血清素的神经元再摄取而起作用。曲马多在肝脏中代谢并进行肾清除,因此它可能需要对肾脏或肾衰竭患者减少剂量或延长给药之间的间隔。
氢可酮是可待因和右丙氧芬的合成衍生物,并且呈现与美沙酮类似的结构。轻度至中度疼痛的患者应使用与NSAID或对乙酰氨基酚相关的弱阿片类药物治疗。如果疼痛不能以治疗剂量控制,则不应考虑改用该组中的另一种药物,而应使用更有效的阿片类药物。
阿片类药物通过结合受体μ、κ和δ而起作用,并且根据它们内在活性可以分为激动剂(吗啡、芬太尼、羟考酮、氢吗啡酮、美沙酮、哌替啶),部分激动/拮抗剂(丁丙诺啡)和激动/拮抗剂(喷他佐辛)。纯激动剂是对μ受体和其它受体施加作用的药物。部分激动剂/拮抗剂在受体上施加部分激动剂作用,并对至少一种受体施加拮抗剂作用,激动剂/拮抗剂对受体施加纯激动剂作用,并对至少一种受体施加拮抗剂作用。
阿片类药物诱导可预期的不良副作用,如果不使其最小化可能妨碍剂量滴定和患者的治疗依从性。副作用包括呼吸抑制、恶心、呕吐、便秘、尿滞留、欣快、镇静作用、瞳孔缩小、镇咳作用、低血压、心动过缓、认知的变化(幻觉、妄想观念)、痛觉过敏、肌阵挛、消化不良、皮肤瘙痒、耐受性和依赖性。
吗啡可以通过口服或肠胃外途径(皮下和静脉内)给药。静脉内给药需要特殊护理,其使用仅限于住院环境。使用对于皮下给药输注泵。
三环抗抑郁药(阿米替林、去甲替林和地昔帕明)与镇痛药联合使用,特别是与阿片类药物联合,主要用于治疗神经性疼痛。由于其抗胆碱能作用,不良反应包括便秘、口腔干燥、尿滞留和心动过速。
抗惊厥药(卡马西平,奥卡西平,苯妥英钠、丙戊酸钠、氯硝西泮、拉莫三嗪、加巴喷丁、普瑞巴林)也用于治疗疼痛,特别是神经性疼痛。卡马西平和苯妥英钠可引起肝毒性、白细胞减少症和血小板减少症,因此需要监测血药浓度。
皮质类固醇(其中地塞米松最常用于治疗疼痛)与胃肠道疾病、糖尿病、神经精神病和近端肌病的发作相关。
因此,在本领域中仍然需要找到用于治疗疼痛的新的治疗方法,不仅作为疾病的症状而且作为疾病本身。
本发明解决的问题是提供一种替代的、新的和有效的用于治疗疼痛的药剂,其单独或与其它镇痛剂组合提供对疼痛的有效治疗,同时减少副作用,同时保持所需的止痛活性。
发明详述
本发明基于如下发现:光活性化合物(R)-吡吲哚对映体显示出有利的镇痛活性,其可用于治疗和预防疼痛。
本发明的发明人惊讶地发现,光活性的(R)-吡吲哚对映体在α2A肾上腺素受体上显示拮抗效应,这又解释(R)-吡吲哚对映体在对疼痛的治疗处理和预防中的意料不到的活性,特别是神经性疼痛。
当(R)-吡吲哚单独用作单一活性成分或与另外镇痛剂联合治疗时,(R)-吡吲哚显示为用于治疗和预防疼痛,特别是神经性疼痛的有效药剂,其中(R)-吡吲哚已被证明还能增强这些另外的镇痛作用。
因此,本发明的目的是提供(R)-吡吲哚或其药学上可接受的盐作为镇痛剂用于治疗疼痛。
本发明的另一个目的还涉及(R)-吡吲哚或其药学上可接受的盐可以单独提供,或作为一部分与至少一种另外的镇痛剂联合治疗而提供,用于治疗疼痛。
本发明的另一个目的还涉及提供药物组合物,其包含(R)-吡吲哚或其药学上可接受的盐以及可接受的载体、赋形剂和/或适当辅药,用于治疗疼痛。
本发明的另一个目的还涉及提供药物组合物,其包含(R)-吡吲哚或其药学上可接受的盐与至少一种另外的镇痛剂的组合,以及可接受的载体、赋形剂和/或适当辅药,用于治疗疼痛,其中(R)-吡吲哚或其药学上可接受的盐和其它镇痛剂皆以固定剂量或分开的剂量给药,例如同时或按顺序给药。
本发明的另一个目的还涉及(R)-吡吲哚或其药学上可接受的盐,用于与另外的镇痛药的联合治疗,用于增强这些另外的镇痛药在治疗疼痛中的作用。
本发明还提供了一种治疗需要治疗的受试者的疼痛的方法,其特征在于向受试者以单独或与至少一种另外的镇痛剂组合的方式给药有效量的(R)-吡吲哚或其药学上可接受的盐。
本发明还提供了通过增强另外的镇痛剂的效果来治疗有需要的受试者的疼痛的方法,其特征在于向受试者以与另外的镇痛剂组合的方式给药有效量的(R)-吡吲哚或其药学上可接受的盐。
发明的详细描述
在本发明的上下文中,以下术语具有如下所述的含义:
本发明中使用的“疼痛”包括与实际或潜在损伤相关或与这种损伤有关描述的任何不愉快的感觉和情感体验。它包括:外周疼痛、中枢性疼痛和心因性疼痛,并且包括浅表性外周疼痛、深度外周疼痛、躯体深度外周疼痛、内脏深度外周疼痛,由中枢神经中枢(例如脊髓,延髓,丘脑或大脑皮层)的神经损伤引起的疼痛,以及不具有器官基质的心理性疼痛。
此外,“疼痛”包括伤害性或神经性疼痛。伤害性疼痛是由于伤害感受器的激活,由非神经组织的实际或威胁性损伤引起的疼痛,并且伤害性疼痛被分类为躯体的或内脏的。躯体疼痛是由于躯体组织(例如骨、关节、肌肉或皮肤)中的伤害感受性受体的激活。在内脏疼痛中,内脏伤害感受器由不同的病理机制(例如机械损伤、炎症、辐射、毒性剂)活化。内脏和躯体伤害性疼痛可以是急性或慢性的,并且包括癌症疼痛。
根据本发明的“神经性疼痛”可以定义为作为影响躯体感觉系统(即外周神经、背根神经节或背根,或中枢神经系统)的损伤或疾病的直接结果而产生的疼痛,并且包括关联到以下的疼痛:
-神经病变,其是影响神经的功能性病症或病理变化,例如单神经病变(如果其涉及单个神经干),多个单神经病变(如果其连续涉及若干神经干)和多发性神经病变(如果涉及弥漫性双侧的若干神经干)。
-外周神经病变,其可以是感觉、运动或自主神经的病变。最常见的运动临床表现包括肌肉痉挛、阵挛、肌束震颤、肌肉萎缩和肌肉力量或灵巧性的丧失。
-消极感知临床表现,诸如痛觉减退和感觉减退。
-积极感知临床表现,除了刺痛感,麻刺感或耳鸣的感觉之外,例如感觉异常、感觉减退、痛觉过度、痛觉过敏和异常性疼痛。
其中神经性疼痛的实例包括:糖尿病性神经性疼痛(糖尿病性NP)、疱疹后神经痛(PHN)、三叉神经痛和中枢神经性疼痛(脊髓损伤(SCI)、中枢性中风后疼痛(CPSP)相关的疼痛,HIV感染(HIV神经病变)相关的神经病变,创伤后或手术后神经性疼痛、慢性神经根病变、癌相关神经性疼痛、幻觉痛和多病原性神经性疼痛,外周多发性神经病、其特征在于脚和指尖的灼烧和针刺感,其通过行走、痛觉超敏、足部感觉减退而恶化,并且不存在跟腱反射;三叉神经痛,其特征在于严重急性疼痛、中毒性神经病变、压迫性神经病变和创伤,其特征在于自发性刺痛、灼烧痛和电击痛,以及疼痛超敏症——包括触摸痛、针刺痛觉超敏和痛觉过敏,在上唇和鼻子中持续几秒钟的电击痛,其在咀嚼或刷牙时恶化,并且不伴随着神经学检查的变化;腕管综合征,其特征在于在手的第一、第二和第三指和手掌表面的急性疼痛、麻刺感和降低的敏感性,其在夜间恶化,在拇指外展和屈腕试验(Phalen test)中肌肉力量减少;股外侧皮神经的单一神经病变,其特征在于对大腿侧面的烧灼和刺痛感以及皮肤过敏性的限定区域的存在;疱疹后神经痛,其特征在于在出现囊泡后在胸腔区域具有横幅状分布的灼痛,囊泡在皮肤愈合后不会改善,增色皮肤斑点。
术语“另外的镇痛剂的效果的增强作用”是指以固定剂量或分开剂量,例如以同时或按顺序形式,联合给药(R)-吡吲哚和至少一种另外的镇痛剂——包括阿片类药物和麻醉剂,增强另外的镇痛剂的镇痛作用,其允许给药更低剂量的活性剂,并降低不良反应、依赖性和耐受性发生的风险。
对于本发明的目的,当通过手性色谱法或比旋光度计算的对映体纯度等于或大于97%时,其被认为是对映体纯的。
术语“药学上可接受的盐”是指在适当的药物评价范围内的那些盐,其适合用于与人组织和器官和低等动物的组织和器官接触,没有过度的毒性、刺激、过敏反应或类似的,并且与合理的利益/风险比是一致的。药学上可接受的盐在技术上是众所周知的。在本说明书中提及了在本发明的上下文中优选的盐的列表。
本文所用的术语“药学上可接受的载体”是指本领域技术人员已知的任何类型的固体、半固体或惰性流体赋形剂、填充剂、包封或制剂辅助材料。
吡吲哚,2,3,3a,4,5,6-六氢-8-甲基-1H-吡嗪并[3,2,1-j,k]咔唑是具有下式的四环化合物:
吡哚吲哚是一种单胺氧化酶A(MAO-A)的可逆抑制剂,迄今为止用作治疗抑郁症的药物。
吡吲哚具有不对称碳原子,但迄今为止只有外消旋物,(外消旋)-吡吲哚(对应于等量的两种对映体(R)和(S)的混合物)用于药物中。
(R)-吡吲哚对映体具有下式:
对于本发明的目的,(R)-吡吲哚对映体可以例如根据P.Chiap等人在以下文章描述的方法获得“Automated determination of pirlindole enantiomers in plasma byon-line coupling of a pre-column packed with restricted access material to achiral liquid chromatographic column”,药学和生物学期刊,27(2002)447-455。
根据该方法,可以通过R-异氰酸苯乙酯和外消旋吡吲哚衍生,制备LC分离相应的非对映体,水解和重结晶来合成(R)-吡吲哚。
本发明中提供的(R)-吡吲哚是对映体纯的。
本发明基于(R)-吡吲哚对映体显示对α2A肾上腺素能受体的拮抗作用的发现。
在调节疼痛症状的潜在机制中,存在非常相关的肾上腺素能受体的干预。这些受体是儿茶酚胺,特别是去甲肾上腺素(norepinephrine)和肾上腺素(epinephrine)的靶。
有两大类的肾上腺素能受体,α-肾上腺素能受体和β-肾上腺素能受体。α-肾上腺素能受体分为亚组α1和α2。最后,a2肾上腺素能受体具有三种具有高遗传同源性的亚型:肾上腺素能受体α2A,α2B和α2C。这些受体在调节神经递质在交感神经系统的水平和在中枢神经系统的肾上腺素能神经元中的活性中起关键作用。
现有技术状态包括的信息能够断定α2A和α2C受体参与调节从交感神经末梢释放的突触前神经递质和位于中枢神经系统中的去甲肾上腺素能神经元。
α2A肾上腺素能受体在高频神经刺激后抑制神经递质释放,而α2C肾上腺素能受体在存在较低频率的神经刺激时调节神经传递。
然而,在中枢神经系统中,大多数α2A受体位于突触后神经元中与去甲肾上腺素能末端相关。这些α2A受体位于中枢神经系统的区域中,此区域用于调节较高认知功能,例如前额叶皮质。
(R)-吡吲哚及其药学上可接受的形式(其包括(R)-吡吲哚的药学上可接受的盐)是选择性和可逆的抑制单胺氧化酶A型酶的化合物。
此外且出人意料地,(R)-吡吲哚对映体显示对α2A肾上腺素能受体的拮抗作用。
(R)-吡吲哚对映体对α2A肾上腺素能受体的选择性拮抗剂作用证明其用于治疗各种形式的疼痛,并且当与另外的镇痛剂联合治疗时,对这些另外的镇痛剂的镇痛作用有增效作用。
因此本发明提供了(R)-吡吲哚对映体及其药学上可接受的盐,作为替代和新的药剂用于疼痛的预防和治疗处理,更具体地是神经性疼痛,其包括与任何类型的外周神经病变相关的疼痛。
本申请的发明人已经发现,(R)-吡吲哚对映体或其药学上可接受的盐可以单独用作单独的活性成分,或作为一部分与至另外的镇痛剂的联合治疗,用于治疗和预防疼痛。
(R)-吡吲哚作为α2A肾上腺素能受体拮抗剂与阿片类药物的节约效应相关(通过增强这些药物的镇痛活性)。(R)-吡吲哚的阿片类药物的节约效应减少如下副作用的发生机率:恶心和呕吐、嗜睡、瘙痒和荨麻疹、便秘、呼吸抑制、激素失衡、意识模糊、幻觉、神志昏迷、低体温、心动过缓或心动过速、直立性低血压、头晕、头痛、尿潴留、输尿管或胆管痉挛、肌肉僵直、肌阵挛、潮红或耐受。因此,(R)-吡吲哚将有助于降低与使用阿片类药物相关的死亡、工作中断和事故的风险。
事实上,当(R)-吡吲哚对映体或其药学上可接受的盐用于与另外的镇痛剂联合治疗时,这些另外的镇痛药的镇痛效果被加强,使得能够需要较低剂量的活性成分以实现期望的治疗效果,从而降低对这些镇痛药的不良反应、依赖性和耐受性发生的风险。
(R)-吡吲哚对映体或其药学上可接受的盐与至少一种另外的镇痛剂的共同给药,允许将镇痛剂的剂量与非联合治疗中所采用的剂量相比减少25-50%。
共同给药或在(R)-吡吲哚与另外的镇痛剂的联合治疗中的使用包括:(R)-吡吲哚或其药学上可接受的盐与至少一种(两种、三种、四种等)另外的镇痛剂的共同给药,其中活性成分的制剂是固定剂量(单一产品)或分开剂量的产品,其中每种活性成分被配制成以同时或按顺序形式给药的合适形式。
本发明考虑将所述产品以组合包用于联合治疗与使用说明书一起呈现。
根据本发明的在与(R)-吡吲哚或其药学上可接受的盐联合治疗中使用的另外的镇痛剂或药物包含至少一种来自以下列的化合物或药物:降低神经元兴奋性的化合物(例如卡马西平、奥卡西平、艾斯利卡西平、苯妥英钠、丙戊酸)、钙通道拮抗剂(普瑞巴林)、离子型和代谢型谷氨酸受体拮抗剂、γ-氨基丁酸活性增强剂(加巴喷丁)或μ、κ和δ阿片类药物受体激动剂、部分激动剂/拮抗剂和拮抗剂。
此外,患有疼痛或未来可能患有疼痛的患者,更具体的是与任何类型的外周神经病病相关的神经性疼痛、根据本发明可以由以固定的或分开的联合治疗的方式使用(R)-吡吲哚或其药学上可接受的盐和选自以下的至少一种化合物或药物:具有除了降低神经元过度兴奋之外的其他任何作用机制的化合物,例如对乙酰氨基酚、非类固醇消炎药(乙酰水杨酸、双氯芬酸、萘丁酮、尼美舒利、萘丁美酮、依托度酸、吡罗昔康、赖氨酸氯尼辛、二氟尼柳、阿西美辛、葡糖美辛、吲哚美辛、丙谷美辛、奥沙美辛、舒林酸、醋氯芬酸、芬替酸、酮咯酸、佐美酸、美洛昔康、替诺昔康、氯诺昔康、非诺洛芬、芬布芬(fenbufeno)、氟比洛芬、苯恶洛芬、布洛芬、酮洛芬、右酮洛芬、吡洛芬、吲哚洛芬、萘普生、奥沙普秦、噻洛芬(tiaprofen)、右旋布洛芬、甲氯芬那酸、甲芬那酸、氟芬那酸、托芬那酸、尼氟酸、依托芬那酯、阿扎丙宗、肝蛋白、非普拉宗、莫尼氟酯、替尼达普、糖胺聚糖、多硫酸、塞来昔布、罗非昔布、帕瑞昔布、伐地昔布和依托昔布)、葡萄糖胺或双醋瑞因。
本发明预期可以提供包含有效量的(R)-吡吲哚化合物或其药学上可接受的盐的组合物,其根据用于制备药学上有用的组合物的已知方法与一种或多种药学上可接受的载体、赋形剂和辅药组合配制成药物组合物。
这样的制剂在本领域技术人员熟知和容易获得的许多来源中详细描述。例如,由Allen、Loyd V.,Jr等人所编,第22版,Remington's The Science and Practice ofPharmacy描述了可以与本发明组合使用的制剂的制备。
本发明的药物组合物可以配制成直肠、胃肠外、脑池内、阴道内、腹膜内、局部(以粉末、软膏或滴剂的形式)、口服(以液体或固体形式)向人和其它哺乳动物给药,或以口服或鼻喷雾的形式给药。本文所用的术语“肠胃外”是指给药方式,其包括静脉内、肌内、腹膜内、胸骨内、皮下、关节内注射和输注。
用于胃肠外注射的药物组合物包括药学上可接受的无菌或非灭菌的水性或非水性溶液、分散液、悬浮液或乳液,以及用于在无菌可注射溶液或分散液中重构的粉剂。
如果需要并为了更有效的分布,本发明的化合物可以包埋在延长控制释放或定向给药系统中,例如聚合物基质、脂质体和微球体。
向个体给药的(R)-吡吲哚化合物或其药学上可接受的盐的剂量将取决于所需反应,并且可取决于待治疗的受试者、其年龄、健康、体重、治疗频率等。例如根据本发明考虑的剂量水平对于口服给药而言为0.1至10mg/kg,对于静脉内给药为0.01至10mg/kg。
(R)-吡吲哚分子具有仲胺基,其具有碱性特征,从而容易形成酸式盐,在本发明的上下文中其可以是药学上可接受的酸式盐。
代表性的药学上可接受的酸式盐包括但不限于:乙酸盐,己二酸盐,藻酸盐,柠檬酸盐,天冬氨酸盐,苯甲酸盐,苯磺酸盐,硫酸氢盐,丁酸盐,樟脑酸盐,樟脑磺酸盐,双葡糖酸盐,延胡索酸盐,甘油磷酸盐,半硫酸盐,硬脂酸庚酸盐,己酸盐,盐酸盐,氢溴酸盐,碘化氢,2-羟基乙磺酸盐(羟乙基磺酸盐),乳酸盐,马来酸盐,甲磺酸盐,烟酸盐,2-萘磺酸盐,草酸盐,双羟基萘酸盐,果胶酸盐,过硫酸盐,3-苯基丙酸盐,苦味酸盐,新戊酸盐,丙酸盐,琥珀酸盐,酒石酸盐,硫氰酸盐、磷酸盐、谷氨酸盐,碳酸氢盐,对甲苯磺酸盐,十一酸盐和扁桃酸盐。
可以与本发明的(R)-吡吲哚化合物形成优选的药学上可接受的酸式盐的实例包括无机酸,诸如盐酸、氢溴酸、硫酸和磷酸,以及有机酸,诸如甲磺酸、柠檬酸、扁桃酸、琥珀酸和柠檬酸。
优选的药学上可接受的盐是:(R)-吡吲哚-(S)扁桃酸盐、(R)-吡吲哚甲磺酸盐和(R)-吡吲哚柠檬酸盐。
以下实施例旨在说明本发明,并且不应理解为限制本发明的范围。
实施例
实施例1:
R-吡吲哚盐酸盐的片剂
制造片剂通过直接压缩进行,并且包括混合所有组分,使它们过筛并在所需的相对大气湿度下以合适的压缩力压制而成。
定性和定量组成(所述量以总组合物的重量百分比%给出)。
(R)-吡吲哚盐酸盐 | 25.00 |
胶体二氧化硅 | 1.50 |
乳糖一水合物 | 45.50 |
HPMC | 2.00 |
微晶纤维素 | 21.00 |
粗晶交联羧甲基纤维素钠 | 4.00 |
硬脂酸钙 | 1.00 |
R-吡吲哚盐酸盐的片剂
制备片剂通过湿法制粒随后压制进行,其包括用适当溶液将活性成分制粒、干燥并过筛,加入必要的辅药,并在所需的相对大气湿度下用合适的压制力进行压制。
定性和定量组成(量以总组合物的重量百分比%给出)。
(R)-吡吲哚盐酸盐 | 25.00 |
微晶纤维素 | 15.00 |
乳糖一水合物 | 50.00 |
HPMC | 4.00 |
粗晶交联羧甲基纤维素钠 | 5.00 |
硬脂酸钙 | 1.00 |
R-吡吲哚盐酸盐的口服溶液
R-吡吲哚盐酸盐的注射溶液
通过将活性成分溶于水直至完全溶解来制备(R)-吡吲哚盐酸盐口服和可注射溶液。
实施例2:
测试(R)-吡吲哚对映体的α2A肾上腺素能受体拮抗剂活性。
功能性α2A肾上腺素能受体拮抗作用测定在平台中进行,其中表达α2A受体的CHO(中国仓鼠卵巢)细胞的形态学应答被评估。使用(R)-吡吲哚和(外消旋)-吡吲哚作为测试物进行功能测定。
将表达人α2A肾上腺素能受体的CHO细胞在实验前一天在适当的培养基中铺板。将化合物加入孔中,6分钟后读取读数。将来自样品的反应与来自对照的反应进行比较以评估激动剂或拮抗剂活性。由α2A激动剂UK-14304诱导的最大活性的百分比(%最大活性)转变为激动剂活性的百分比,UK-14304(5-溴-N-(2-咪唑啉-2-基)-6-氨基喹喔啉,5-溴-N-(4,5-二氢-1H-咪唑-2-基)-6-氨基喹喔啉,溴莫尼定)由Sigma-Aldrich公司销售。
(R)-吡吲哚对映体和(外消旋)-吡吲哚不同地中和UK-14304对α2A肾上腺素能受体的激动剂活性。出乎意料地,(R)-吡吲哚呈现α2A受体拮抗剂活性。例如,在10μM的浓度下,UK-14304在(R)-吡吲哚(59.72%)存在下的激动剂活性低于(外消旋)-吡吲哚(89.02%)存在下的激动剂活性。因此,(R)-吡吲哚抑制40.28%的激动剂活性,而(外消旋)-吡吲哚仅抑制10.98%的激动剂活性。因此,(外消旋)-吡吲哚对α2A肾上腺素能受体呈现比(R)-吡吲哚小约四倍(4×)的拮抗剂活性。
表1:由UK-14304诱导的最大激动剂活性的百分比。
这些意想不到的结果维持(R)-吡吲哚用于治疗疼痛,特别是神经性疼痛综合征的益处。
Claims (12)
1.(R)-吡吲哚对映体或其药学上可接受的盐用于治疗处理或预防疼痛的用途。
2.根据权利要求1所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其特征在于所述(R)-吡吲哚是对映体纯的。
3.根据权利要求1和2所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其用于与至少一种另外的镇痛剂的联合治疗。
4.根据权利要求3所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其中所述联合治疗包括固定剂量的联合治疗或选自将活性剂按顺序给药或同时给药的分开的联合治疗。
5.根据权利要求3和4所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,用于增强所述至少一种另外的镇痛剂在治疗疼痛中的效果。
6.根据权利要求1至5中任一项所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其是(S)-吡吲哚(R)-扁桃酸盐的形式。
7.根据权利要求1至5中任一项所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其是(R)-吡吲哚甲磺酸盐的形式。
8.根据权利要求1至5中任一项所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其是(R)-吡吲哚柠檬酸盐的形式。
9.根据权利要求3至8中任一项所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其特征在于,所述至少一种另外的镇痛剂是降低神经元兴奋性的化合物,其选自:钠通道抑制剂(酰胺咪嗪、奥卡西平、艾司利卡西平、苯妥英、丙戊酸)、钙通道拮抗剂(普瑞巴林)、离子型和代谢型谷氨酸受体拮抗剂、γ-氨基丁酸活性增强剂(加巴喷丁)或μ、κ和δ阿片类药物受体激动剂、部分激动剂/拮抗剂或拮抗剂。
10.根据权利要求3至8所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其特征在于,所述至少一种另外的镇痛剂选自以下的化合物:扑热息痛、非类固醇抗炎药(乙酰水杨酸、双氯芬酸、萘丁酮、尼美舒利、萘丁美酮、依托度酸、吡罗昔康、赖氨酸氯尼辛、二氟尼柳、阿西美辛、葡糖美辛、吲哚美辛、丙谷美辛、奥沙美辛、舒林酸、醋氯芬酸、芬替酸、酮咯酸、佐美酸、美洛昔康、替诺昔康、氯诺昔康、非诺洛芬,芬布芬、氟比洛芬、苯恶洛芬、布洛芬、酮洛芬、右酮洛芬、吡洛芬、吲哚洛芬、萘普生、奥沙普秦、噻洛芬、右旋布洛芬、甲氯芬那酸、甲芬那酸、氟芬那酸、托芬那酸、尼氟酸、依托芬那酯、阿扎丙宗、肝蛋白、非普拉宗、莫尼氟酯、替尼达普、糖胺聚糖、多硫酸、塞来昔布、罗非昔布、帕瑞昔布、伐地昔布和依托昔布)、葡萄糖胺或双醋瑞因。
11.根据前述权利要求中任一项所述的(R)-吡吲哚对映体或其药学上可接受的盐的用途,其中疼痛是神经性疼痛。
12.用于治疗疼痛的药物组合物,其包含根据前述权利要求中任一项所述的(R)-吡吲哚对映体或其药学上可接受的盐以及药学上可接受的载体、赋形剂或辅药。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/PT2014/000028 WO2015171004A1 (en) | 2014-05-09 | 2014-05-09 | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106413714A true CN106413714A (zh) | 2017-02-15 |
Family
ID=50819930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480078733.5A Pending CN106413714A (zh) | 2014-05-09 | 2014-05-09 | (r)‑吡吲哚及其药学上可接受的盐的药学用途 |
Country Status (28)
Country | Link |
---|---|
US (2) | US20170145015A1 (zh) |
EP (1) | EP3054950B1 (zh) |
JP (1) | JP2017514884A (zh) |
KR (1) | KR102232198B1 (zh) |
CN (1) | CN106413714A (zh) |
AU (1) | AU2014393489B2 (zh) |
CA (1) | CA2948596C (zh) |
CY (1) | CY1119522T1 (zh) |
DK (1) | DK3054950T3 (zh) |
EC (1) | ECSP16086232A (zh) |
ES (1) | ES2649491T3 (zh) |
HR (1) | HRP20171650T1 (zh) |
HU (1) | HUE035030T2 (zh) |
IL (1) | IL248854B (zh) |
LT (1) | LT3054950T (zh) |
MA (1) | MA39448B1 (zh) |
MX (1) | MX368735B (zh) |
NO (1) | NO3054950T3 (zh) |
NZ (1) | NZ726131A (zh) |
PH (1) | PH12016502236A1 (zh) |
PL (1) | PL3054950T3 (zh) |
PT (1) | PT3054950T (zh) |
RS (1) | RS56590B1 (zh) |
RU (1) | RU2695607C2 (zh) |
SI (1) | SI3054950T1 (zh) |
TN (1) | TN2016000497A1 (zh) |
UA (1) | UA116499C2 (zh) |
WO (1) | WO2015171004A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS56590B1 (sr) | 2014-05-09 | 2018-02-28 | Tecnimede Sociedade Tecnico Medicinal S A | (r)-pirlindol i njegove farmaceutski prihvatljive soli za upotrebu u medicini |
AU2014393487B2 (en) * | 2014-05-09 | 2020-01-02 | Tecnimede Sociedade Tecnico-Medicinal S.A. | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine |
KR102421013B1 (ko) | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
WO2019241564A1 (en) * | 2018-06-13 | 2019-12-19 | Children's Medical Center Corporation | Biomarkers of neuropathic pain |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040106681A1 (en) * | 2002-10-03 | 2004-06-03 | Cypress Bioscience, Inc. | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006512417A (ja) * | 2002-12-24 | 2006-04-13 | ニューロケム (インターナショナル) リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
NZ545484A (en) * | 2003-09-15 | 2009-09-25 | Vectura Ltd | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
HUE035071T2 (en) * | 2014-05-09 | 2018-05-02 | Tecnimede Sociedade Tecnico Medicinal S | (S) -pirlindole and its pharmaceutically acceptable salts for use in medicine |
RS56590B1 (sr) | 2014-05-09 | 2018-02-28 | Tecnimede Sociedade Tecnico Medicinal S A | (r)-pirlindol i njegove farmaceutski prihvatljive soli za upotrebu u medicini |
AU2014393487B2 (en) * | 2014-05-09 | 2020-01-02 | Tecnimede Sociedade Tecnico-Medicinal S.A. | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine |
-
2014
- 2014-05-09 RS RS20171093A patent/RS56590B1/sr unknown
- 2014-05-09 TN TN2016000497A patent/TN2016000497A1/en unknown
- 2014-05-09 DK DK14726443.6T patent/DK3054950T3/da active
- 2014-05-09 WO PCT/PT2014/000028 patent/WO2015171004A1/en active Application Filing
- 2014-05-09 CN CN201480078733.5A patent/CN106413714A/zh active Pending
- 2014-05-09 US US15/309,916 patent/US20170145015A1/en not_active Abandoned
- 2014-05-09 NZ NZ726131A patent/NZ726131A/en unknown
- 2014-05-09 MA MA39448A patent/MA39448B1/fr unknown
- 2014-05-09 ES ES14726443.6T patent/ES2649491T3/es active Active
- 2014-05-09 HU HUE14726443A patent/HUE035030T2/en unknown
- 2014-05-09 KR KR1020167031372A patent/KR102232198B1/ko active IP Right Grant
- 2014-05-09 UA UAA201611333A patent/UA116499C2/uk unknown
- 2014-05-09 JP JP2016567556A patent/JP2017514884A/ja active Pending
- 2014-05-09 MX MX2016014701A patent/MX368735B/es active IP Right Grant
- 2014-05-09 NO NO14726443A patent/NO3054950T3/no unknown
- 2014-05-09 PL PL14726443T patent/PL3054950T3/pl unknown
- 2014-05-09 LT LTEP14726443.6T patent/LT3054950T/lt unknown
- 2014-05-09 SI SI201430470T patent/SI3054950T1/sl unknown
- 2014-05-09 PT PT147264436T patent/PT3054950T/pt unknown
- 2014-05-09 CA CA2948596A patent/CA2948596C/en active Active
- 2014-05-09 AU AU2014393489A patent/AU2014393489B2/en active Active
- 2014-05-09 RU RU2016148182A patent/RU2695607C2/ru active
- 2014-05-09 EP EP14726443.6A patent/EP3054950B1/en active Active
-
2016
- 2016-11-09 PH PH12016502236A patent/PH12016502236A1/en unknown
- 2016-11-09 IL IL248854A patent/IL248854B/en active IP Right Grant
- 2016-11-09 EC ECIEPI201686232A patent/ECSP16086232A/es unknown
-
2017
- 2017-10-30 CY CY20171101122T patent/CY1119522T1/el unknown
- 2017-10-30 HR HRP20171650TT patent/HRP20171650T1/hr unknown
- 2017-12-19 US US15/846,440 patent/US10533012B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040106681A1 (en) * | 2002-10-03 | 2004-06-03 | Cypress Bioscience, Inc. | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
Non-Patent Citations (5)
Title |
---|
JAIME C.BRANCO等: "Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome", 《CLINICAL DRUG INVESTIGATION》 * |
JARDEL GOMES VILLARINHO等: "Progress in Neuro-Psychopharmacology & Biological Psychiatry", 《PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY》 * |
P.CHIAP等: "Automated determination of pirlindole enantiomers in plasma by on-line coupling of a pre-column packed with restricted access material to a chiral liquid chromatographic column", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
PASCAL DE TULLIO等: "Effective Resolution of Racemic Pirlindole at the Preparative Scale", 《CHIRALITY》 * |
WINFRIED HAUMSER等: "Treatment of Fibromyalgia Syndrome With Antidepressants", 《JAMA》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106456637A (zh) | (s)‑吡吲哚及其药学上可接受的盐的药学用途 | |
EP0591434A1 (en) | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron | |
US10533012B2 (en) | (R)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
CN105813638A (zh) | 包含trpa1拮抗剂和镇痛剂的药物组合物 | |
RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
WO2011133212A1 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
JP6116679B2 (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよび抗けいれん剤を含む医薬組成物 | |
CA3069462A1 (en) | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | |
Ray et al. | M100907 and BD 1047 attenuate the acute toxic effects of methamphetamine | |
JP6116678B2 (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびNSARを含む医薬組成物 | |
JP4427329B2 (ja) | 慢性疼痛の治療のための2−インダニルアミノ誘導体 | |
US9265774B2 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
JP2015516449A (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物 | |
WO2014155184A1 (en) | Treatment for parkinson's disease | |
WO2013175316A2 (en) | Treatment for huntington's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |